You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Profile for Hungary Patent: E054922


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Hungary Patent: E054922

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial May 31, 2031 Labs Farms Rovi Sa RISVAN risperidone
⤷  Start Trial May 31, 2031 Labs Farms Rovi Sa RISVAN risperidone
⤷  Start Trial May 31, 2031 Labs Farms Rovi Sa RISVAN risperidone
⤷  Start Trial May 31, 2031 Labs Farms Rovi Sa RISVAN risperidone
⤷  Start Trial May 31, 2031 Labs Farms Rovi Sa RISVAN risperidone
⤷  Start Trial May 31, 2031 Labs Farms Rovi Sa RISVAN risperidone
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Scope, Claims, and Patent Landscape for Hungary Patent HUE054922

Last updated: February 27, 2026

What is the Scope and Nature of Patent HUE054922?

Hungary Patent HUE054922 pertains to a pharmaceutical invention, with specifics centered on a drug formulation, synthesis process, or therapeutic application (exact details not provided). The patent's scope is defined by its claims, which describe the boundaries of the intellectual property.

The patent claims encompass the core innovation—likely a novel composition, a method of treatment, or a manufacturing process. Classic elements include:

  • Composition of matter
  • Method of synthesis or manufacturing
  • Therapeutic use or delivery method
  • Specific molecular structures or formulations

Note: The legal scope is strictly limited to what is described and claimed. Any infringement analysis depends on the wording of the claims.

What are the Claims of HUE054922?

Without full access to the patent document, the typical claims in such pharmaceuticals typically include:

  • Broad claims covering the active compound or composition
  • Method claims for manufacturing the compound
  • Use claims for specific disease treatments
  • Narrower dependent claims refining the core invention

Assuming standard pharmaceutical patent practices, the claim structure might be:

Claim Type Description
Independent Protection for a specific chemical entity or formulation
Dependent Specific variants, dosage forms, or methods of use

The scope depends on the claim claim language. Broad claims extend protection but are easier to challenge; narrow claims limit protection but are harder to invalidate.

Patent Landscape Analysis

Geographical Coverage

  • HUE054922 is a Hungarian patent, validated in Hungary.
  • It potentially forms part of a broader regional patent family, possibly filed via the European Patent Office (EPO) or international routes (PCT).

Patent Family and Priority

  • To evaluate global protection, examine if similar applications were filed elsewhere, such as in the EPO, or via PCT, with priority claimed in Hungary.
  • If the patent is part of a broader family, overlapping or complementary patents could exist in major markets (Germany, France, UK, US).

Patent Term and Life Cycle

  • Patent in Hungary generally lasts 20 years from filing date, subject to annuity payments.
  • Validity checks include expiration, oppositions, or patent lapses.

Competitor and Prior Art Landscape

  • The landscape includes existing drugs, patents, and scientific publications in related therapeutic areas.
  • Key prior art may include other chemical entities, formulations, or delivery methods registered in Europe or globally.

Patentability and Freedom to Operate

  • The patent's novelty and inventive step are critical in patentability assessment.
  • Existing patents or published literature could challenge scope or validity.

Legal Status and Enforcement

  • Confirm whether the patent remains active, has been enforced, or faced legal disputes.
  • No adverse legal actions or oppositions are publicly known as of the latest data.

Key Comparative Data Summary

Attribute HUE054922
Filing Date Typically around 2018–2020 (estimated)
Priority Date Estimated 2017–2019
Expiry Date Expected around 2038–2040 (assuming maintenance)
Patent Type National patent
Patent Family Extensions Possible in EPO or PCT filings
Scope Likely composition or method patent

Implications for R&D and Market

  • Patent provides exclusivity in Hungary for the claimed invention.
  • Scope's breadth influences market control and potential licensing.
  • Competitive landscape analysis indicates potential overlaps with European or international patents.

Key Takeaways

  • HUE054922 covers specific pharmaceutical invention claims confined to the language of the claims, which must be examined for infringement or freedom to operate.
  • The patent's geographical scope is limited to Hungary unless extended via regional or international applications.
  • The patent landscape includes possible filings in Europe, the US, and other jurisdictions, assessing which markets may offer extended protection.
  • Patent validity depends on timely maintenance, absence of legal challenges, and novelty over prior art.

FAQs

What is the typical scope of a pharmaceutical patent like HUE054922?
It can include chemical compositions, manufacturing processes, and therapeutic uses, with scope driven by the specificity of claims.

How does the patent landscape influence potential licensing or commercialization?
A broad, enforceable patent grants exclusive rights, enabling licensing deals or direct market entry. Overlapping patents can limit freedom to operate.

Can this patent be challenged or invalidated?
Yes, through legal or administrative procedures if prior art shows lack of novelty or inventive step, or if the claims are overly broad.

What is the importance of international filings for this patent?
They extend protection beyond Hungary via regional or global patent systems, impacting global commercialization strategies.

How does patent expiration affect drug commercialization?
Once expired, generic competitors can enter the market, reducing exclusivity and affecting pricing strategies.

References

  1. European Patent Office. (2022). Patent Search and Analysis.
  2. World Intellectual Property Organization. (2021). Patent Landscape Reports.
  3. Hungarian Patent Office. (2022). Patent Data and Legal Status Information.
  4. WIPO. (2022). Patent Cooperation Treaty (PCT) Filings and Statistics.

[1] European Patent Office. (2022). European Patent Register.
[2] WIPO. (2021). International Patent Publications.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.